Kornimate/medical-research-clean huggingface dataset:
protein tyrosine kinases (ptk) in multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to determine whether or not cancer cells in the body are affected by ptk and whether it affects the growth of these cells.

patients will take ptk orally once a day for the duration of their time on the study. each cycle of chemotherapy will last for 4 weeks. measurement of vital signs will be done weekly during the first month of treatment. physical exam, vital signs, blood work, a quality of life assessment, and x-ray or mri wil be performed every 4 weeks. patients will remain on the study until their disease fails to respond to treatment or there are intolerable side effects. typically treatment is performed for 12 weeks and up to one year in patients that are stable and responding.

Eligibility criteria:
inclusion criteria: * older than 18 years of age. * confirmed diagnosis of active progressive multiple myeloma * history of \> 2 prior cytotoxic treatment regimens. bone marrow transplantation will be considered as one regimen. * current measurable disease based on serum and/or urine m protein and/or measurable plasmacytoma. * eastern cooperative oncology group (ecog) performance status of 0-2 * absolute neutrophil count (anc) \> 1,500 mm3 * platelets \> 100,000 mm3 * serum creatinine \< 1.5 upper limit of normal (uln) * serum bilirubin \< 1.5 uln * ast/agot and alt/sgpt \< 3.0 uln * life expectancy \> 12 weeks exclusion criteria: * chemotherapy \< 3 weeks prior to registration. * biologic or immunotherapy \< 2 weeks prior to registration * full field radiotherapy \< 4 weeks or limited field radiotherapy \< 2 weeks prior to registration. * history or presence of central nervous system (cns) disease * history of leukemia * history of another primary malignancy with the exception of inactive basal or squamous cell carcinoma of the skin * major surgery \< 4 weeks prior to registration * prior therapy with anti-vascular endothelial growth factor (vegf) agents excluding thalidomide, revimid, velcade and arsenic trioxide * interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung * pleural effusion or ascites that cause respiratory compromise * female patients that are pregnant or breast feeding * uncontrolled high blood pressure, history of labile hypertension or history of poor compliance with an antihypertensive regimen * unstable angina pectoris * symptomatic congestive heart failure * myocardial infarction \< 6 months prior to registration * serious uncontrolled cardiac arrhythmia * uncontrolled diabetes * active or uncontrolled infection * acute or chronic liver disease * impairment of gastrointestinal (gi) function or gi disease * confirmed hiv infection

Keywords: multiple myeloma ptk relapsed multiple myeloma refractory multiple myeloma myeloma
a trial of restrictive versus traditional blood transfusion practices in burn patients

Conditions: Burn Injury

Summary: the purpose of this study is to find out if burn injured patients do better receiving fewer blood transfusions than what is traditionally given. we traditionally provide blood transfusions to maintain a hemoglobin level, which is an indicator of the level of red blood cells that carry oxygen in your body, to above 10 g/dl (g/dl stands for grams per deciliter and is the standard measurement used to indicate the level of red blood cells in your blood). however, a preliminary study indicated that maintaining the hemoglobin level to above 7-8 g/dl with less blood transfusion, as compared to a hemoglobin level of 10 g/dl and above, would reduce the occurrence of blood infection, duration on the respirator and length of hospital stay, yet would achieve similar survival in both groups.


Eligibility criteria:
inclusion criteria: * \>20% tbsa burn with anticipated operation need on admission as determined by attending physician * age \>18 years * admission within 96 hours of injury exclusion criteria: * \<18 years of age * pregnancy * inability or unwillingness to receive blood products * history of chronic anemia (hemoglobin \<9.0 g/dl one month prior to enrollment) * preexisting need for hemodialysis * brain death or imminent brain death * non-survivable burn as determined by the attending burn surgeon * angina or acute myocardial infarction * preexisting hematologic disease * length of hospital stay anticipated to be \< 2 weeks * transfusion administered at outside hospital before admit

Keywords: burn transfusion blood hemoglobin
validity and reliability of vietnamese version of 17items-hamilton depression rating scale

Conditions: Depression, Unipolar

Summary: this reseach examines the reliability and validity of 17 items- hamilton depression rating scale in vietnamese population, which has been commonly used in clinical depression practice and study.

- cross-sectional study

Eligibility criteria:
inclusion criteria: * patients accept paticipating in reasearch exclusion criteria: * patients don't answer full hrds
comparison between topical mitomycin c and cyclosporine

Conditions: Pterygium

Summary: pterygium is a disease associated with proliferation of the fibrovascular tissues of the conjunctiva into the cornea and is related to factors such as ultraviolet light exposure, chronic stimulation, inflammation, climate, and genetics.

the first line of treatment for primary pterygium is surgical excision, and despite postoperative adjuvant therapy using mitomycin c, cyclosporine, β-irradiation, argon laser, and bevacizumab, recurrence rates remain high . mitomycin c is a metabolic inhibitor extracted from streptomyces caespitosus that inhibits dna synthesis . cyclosporine is an immunosuppressant that selectively suppresses t-helper cells, controls interleukin synthesis and secretion, and inhibits vascular endothelial growth factor (vegf) bevacizumab is an anti-vegf antibody that inhibits angiogenesis. each agent has been studied as an adjuvant therapy to inhibit post-surgery pterygium recurrence.

Eligibility criteria:
inclusion criteria: * diagnosis of primary pterygium * pterygium size \> or equal 2mm (the horizontal length of the tissue from limbus to cornea will be measured by slit lamp biomicroscopy). * ocular discomfort refractory to medical treatment. * visual loss induced by pterygium. * adult egyptian population exclusion criteria: * patients who had recurrent pterygium or allergy to topical cyclosporine. * patients who had allergy from mitomycin c. * pregnant women. * patients with uncontrollable systemic diseases such as hypertension, diabetes, or cardiovascular diseases. * patients with diseases of the eye surface such as conjunctivitis and keratitis. * patients with a history of eye surgery within the previous six months.
donor stem cell transplant in treating patients with mantle cell lymphoma

Conditions: Lymphoma

Summary: rationale: giving chemotherapy and monoclonal antibody therapy before a donor stem cell transplant helps stop the growth of cancer cells. it also helps stop the patient's immune system from rejecting the donor's stem cells. when the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. purpose: this phase ii trial is studying donor stem cell transplant in treating patients with mantle cell lymphoma.

objectives: primary * determine progression-free survival in patients with mantle cell lymphoma undergoing low-intensity allogeneic stem cell transplantation. secondary * determine overall survival of these patients. * determine the toxicity by way of adverse event profile of this regimen in these patients. outline: this is a multicenter study. * reduced intensity conditioning: patients receive carmustine iv over 2 hours on day -6, etoposide iv over 1 hour and cytarabine iv over 15 minutes on days -5 to -2, alemtuzumab iv over 2 hours on days -5 to -1, and melphalan iv on day -1. * donor stem cell transplant: patients undergo stem cell transplantation on day 0 with filgrastim (g-csf)-mobilized peripheral blood stem cells or bone marrow stem cells. * graft-versus-host disease (gvhd) prophylaxis: patients receive cyclosporine iv or orally on day -1 to 30 and taper to day 100. * donor lymphocyte infusion (dli) therapy: patients with evidence of disease progression, mixed chimerism, or low level residual disease undergo dli every 3 months for up to 15 months in the absence of gvhd. after completion of study, patients are followed every 3 months for 2 years.

Eligibility criteria:
disease characteristics: * histologically confirmed diagnosis of mantle cell lymphoma * no relapsed or progressive disease * achieved at least a partial remission following induction chemotherapy * hla-matched donor available * blood samples from both patient and donor available for chimerism studies * no central nervous system involvement patient characteristics: * ecog performance status 2-4 * considered fit for transplant by treating physician * serum bilirubin ≤ 1.5 times upper limit of normal * alkaline phosphatase ≤ 2 times normal * creatinine clearance ≥ 50 ml/min * ejection fraction \> 50% (no inadequate cardiac function) * not pregnant or nursing * negative pregnancy test * no symptomatic respiratory compromise * no serious concurrent disease which would preclude allograft * no known serological positivity for hepatitis b, hepatitis c, or hiv * no history of a psychological illness or condition that would affect compliance * no previous malignancy within the past 5 years except nonmelanoma skin tumors or stage 0 (in situ) cervical carcinoma prior concurrent therapy: * see disease characteristics

Keywords: stage iii mantle cell lymphoma stage iv mantle cell lymphoma
stopping hypertension and improving children's lives after kidney transplantation

Conditions: Arterial Hypertension; Kidney Transplant; Complications

Summary: cardiovascular (cv) disease is a major morbidity in children after kidney transplantation (ktx), limiting life expectancy and impairing graft function. arterial hypertension (ah) is the dominant cv risk factor, and highly abundant in this patient group. ah can cause left ventricular hypertrophy (lvh), which is predictive of cv death. lvh can be non-invasively assessed by measuring left ventricular mass index (lvmi). analyses of observational data showed that blood pressure (bp) levels \ 12 months after ktx at several ktx centers. patients will be randomly assigned 1:1 to an intensified bp management group (bp target ≤60th pct) and a standard bp management group (bp target \<90th pct). the primary endpoint is lvmi after 24 months. secondary endpoints are estimated glomerular filtration rate (egfr), pulse wave velocity (pwv) and intima media thickness (imt) after 24 months. bp control will be guaranteed for both groups through bp telemonitoring, which will be transmitted in real time to the treating physician and the trial's centralized bp office. by defining the adequate bp goal, the results of the proposed study will have direct implications for the care of children after ktx. the results will define an important element of post-ktx care and help to lower cv morbidity and subsequently cv mortality of pediatric ktx patients.


Eligibility criteria:
inclusion criteria: * kidney transplantation \&gt;12 months ago * arterial hypertension exclusion criteria: * cardiac malformation * treatment for a rejection episode within three months prior to inclusion

Keywords: left ventricular mass pediatric kidney transplantation
the impact of using triclosan-antibacterial sutures on the incidence of surgical site infection

Conditions: Surgical Site Infection

Summary: to compare conventional polyglactin 910 sutures with triclosan-coated polyglactin 910 antimicrobial sutures for the reduction of surgical site infections and any associated health and economic benefits.


Eligibility criteria:
inclusion criteria: * all patients of different age * gender * risk factors and procedures candidate for surgical intervention during the period of the study exclusion criteria: * patients with an established pre-operative infection at the operative site

Keywords: surgical site infection antimicrobial triclosan-coated polyglactin 910 suture length of hospital stay ssi
producerx: improving weight and cardiovascular risk in adults with food insecurity and obesity

Conditions: Obesity

Summary: this is a pilot randomized controlled trial to assess the effects of providing produce vouchers during behavioral weight loss treatment in 40 adults with obesity and food insecurity. participants will be randomized to producerx (12 weekly sessions of in-person, behavioral weight loss counseling (bwl) + produce prescriptions) or a waitlist control (wlc).

the proposed investigation is a single-site, pilot rct to assess the effect of bwl and produce vouchers (producerx) on diet quality, weight loss and cardiovascular risk factors among adult participants with food insecurity and obesity. adults (n=40) will be randomized to a 12-week program that provides weekly, 30-minute bwl sessions + produce vouchers (n=20) or wlc (n=20). outcomes will be assessed at baseline and at 12 weeks and include questionnaires, and measurements of weight, height, and cardiometabolic risk factors (blood pressure, waist circumference, and pulse). participants will also be asked to complete two 24-hour dietary recalls.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. bmi ≥ 30 kg/m2 3. food insecurity as assessed by the two-item "hunger vital sign" 4. subjects must: 1. have reliable telephone or internet service to communicate with study staff 2. plan to remain in the philadelphia area for the next 6 months or more 5. understand and be willing to comply with all study-related procedures and agree to participate in the study by giving written informed consent. exclusion criteria: 1. pregnant, nursing, or plans to become pregnant in the next 6 months 2. serious medical risk such as uncontrolled diabetes, cancer, congestive heart failure, or recent cardiac event (e.g., myocardial infarction or stroke within the past 6 months) 3. clinically significant hepatic or renal disease 4. history of (or plans for) bariatric surgery 5. current psychiatric disorder that significantly interferes with daily living 6. self-reported alcohol or substance abuse within the past 12 months 7. use in past 3 months of medications known to induce significant weight loss (i.e., prescription weight loss medications) or weight gain (e.g., chronic use of oral steroids, second generation antipsychotics) 8. loss of ≥ 10 lb of body weight within the past 3 months 9. participation in a structured weight loss program in the prior 6 months 10. inability to walk 2 blocks comfortably or engage in some other form of aerobic activity (e.g., swimming) 11. participant from same household 12. inability to attend treatment and/or assessment visits 13. lack of capacity to provide informed consent 14. any serious or unstable medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safety or successful participation in the study

Keywords: food insecurity
effects of concurrent hiit and wb-ems exercise on the cardiometabolic risk profile in obese individuals

Conditions: Overweight and Obesity; Metabolic Syndrome

Summary: the main purpose of this study is to compare the impact of concurrent high-intensity interval training (hiit) and whole-body electromyostimulation exercise (wb-ems) or low-volume conventional strength training (cst) on the cardiometabolic risk profile, overall physical fitness (cardiorespiratory fitness and muscular strength), body composition, inflammatory markers and subjective health outcomes after a 12-week intervention trial in overweight individuals at increased cardiometabolic risk. furthermore, this study aims to investigate the influence of intra-session exercise order on all outcomes.


Eligibility criteria:
inclusion criteria: * body mass index \>25 * presence of at least 2 cardiometabolic risk factors exclusion criteria: * healthy persons or patients under age * overweight persons without any additional cardiometabolic risk factors * pregnancy, lactation * psychological disorders, epilepsy, sever neurological disorders * participation in other exercise- or nutrition studies within the last 6 months * acute cardiovascular disease * malignant disease * electronic implants (defibrillator, pacemaker) * persons in mental hospitals by order of authorities or jurisdiction

Keywords: cardiometabolic health cardiorespiratory fitness muscular strength body composition inflammation aerobic exercise resistance exercise
nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism

Conditions: Autism Spectrum Disorder; Aggression; Irritability

Summary: some individuals with autism spectrum disorders (asd) also demonstrate irritability or aggression, which can interfere with functioning. the purpose of this pilot study is to test whether transdermal nicotine is effective for irritability and/or aggression in adults with asd using a double-blind, placebo-controlled clinical trial. subjects will participate in three visits. at the first visit, subjects are screened for eligibility and enrolled. baseline measures include rating scales and a frustrative computerized task. they will then wear seven days of transdermal nicotine or placebo. visit two is on day seven and the study measures are repeated, vital signs and side effects monitored. subjects will return for a third and final visit on day 21 to repeat the study measures performed during visit two.


Eligibility criteria:
inclusion criteria: * age: 18-60 * gender: all * language: communicative in english * participants with a prior diagnosis of dsm-5 asd at some point in their lifetime or a dsm-4 diagnosis of autism or a dsm-4 diagnosis of asperger's syndrome or a dsm-4 diagnosis of pervasive developmental disorder not otherwise specified. * symptoms of irritability, agitation or aggression as reported by parent and/or participant * aberrant behavior checklist - irritability subscale (abc-i) score of 16 or higher * no changes in psychotropic medications within the past 14 days. * either lives with a primary caregiver or closely engaged with a primary caregiver who interacts with the patient daily * bmi \> 17.5 and \< 45 exclusion criteria: * age \ 60 * bmi \ 45 * currently using tobacco or any nicotine products (transdermal, gum, e-cigarettes) * changes in psychotropic medication management within the past 14 days * previous allergy to transdermal patches * patients with heart rate \> 100 or \< 50 or known history of cardiac rhythm abnormalities * systolic blood pressure \> 150 or \ 90 or \< 50 * no symptoms of irritability, agitation, or aggression as reported by parent and/or participant * abc-i score of less than 16 * no primary caregiver, or primary caregiver unable to assist with rating scales

Keywords: autism spectrum disorder aggression irritability nicotine nicotinic acetylcholine receptor nicotinic agonist adult autism
efficacy study of prucalopride to treat chronic intestinal pseudo-obstruction (cip)

Conditions: Chronic Intestinal Pseudo-Obstruction

Summary: this study was designed to investigate the clinical safety, tolerability and efficacy of prucalopride in improving the symptoms associated with chronic intestinal pseudo-obstruction (cip) in subjects with cip. the study hypothesis was that prucalopride at doses up to 4 mg is safe, well tolerated, efficacious and improves the symptoms associated with cip.

this phase ii, double-blind, placebo-controlled, two-treatment four periods cross-over trial investigated the clinical safety, tolerability and the efficacy of r093877 (prucalopride) in improving the symptoms associated with chronic intestinal pseudo-obstruction (cip) in subjects with cip. subjects were treated for 4 periods of 12 weeks each with either r093877 2 mg (2 periods) or placebo (2 periods). in each of the first and second 6 month period, there was a placebo (pla) and an active drug (pru) treatment period. there were no wash-out periods. in total,7 subjects were randomized; 2 were assigned to the pla-pru-pla-pru, 2 to the prupla-pru-pla, 2 to the pla-pru-pru-pla, and 1 to the pru-pla-pla-pru sequence group. subjects were allowed to use up to 4 mg of prucalopride per day if the 2 mg dose seemed to be insufficient. two subjects used an average of 3 mg of prucalopride per day during the active drug periods.

Eligibility criteria:
inclusion criteria: * aged ≥ 18 years; * a history of chronic pseudo-obstruction for at least 3 months; * subjects with chronic idiopathic pseudo-obstruction or chronic pseudo-obstruction secondary to scleroderma or intestinal polyneuropathy; * cip had been diagnosed by a barium-imaging study showing the presence of dilatation of any part of the small bowel (with or without the presence of large bowel dilatation); exclusion criteria: * subjects with organic obstructing lesions causing intestinal obstruction; * current uncontrolled cardiovascular or lung disease, neurologic or psychiatric disorders (including substance abuse but with the exception of nicotin), alcoholism, cancer or aids and endocrine disorder; * impaired renal function * a serum amylase, a serum glutamic-oxaloacetic transaminase (sgot) or a serum glutamic-pyruvic transaminase (sgpt)concentration of \> 2 times the normal limit; * laboratory values outside the reference range of the laboratory, unless explained by the disease or felt by the investigator to be clinically unimportant; * use of disallowed concomitant therapy; * female subjects who were pregnant or wished to become pregnant during the course of the trial or who were lactating;
the therapy effect of azathioprine initial or 14 weeks after combined with infliximab on cd

Conditions: Crohn Disease

Summary: this study aim to identify the therapeutic effect of azathioprine during infliximab(ifx) treatment in crohn's disease (cd).half of patients will receive azathioprine and infliximab combination therapy at the same time. the other half patients will be given infliximab therapy first and then receive azathioprine 14 weeks later.

anti-tumor necrosis factor agents were widely used for many years and were proved to be most reliable drugs in crohn's disease (cd). about one-third of the patients would develop a secondary lost of response after initiating ifx therapy in one year follow-up. immunosuppressor was thought to be a useful agent to reduce loss of response rate of infliximab.but it remain unclear when should us add immunosuppressor during infliximab therapy.this study aim to find the most valuable timepoint to initiate combination therapy to maximize therapeutic effect and minimize the adverse effect.

Eligibility criteria:
inclusion criteria: - cd patients need infliximab and azathioprine combination therapy exclusion criteria: - patients had lost response to infliximab or azathioprine previously patients intolerable to infliximab or azathioprine patients need to use 5-aminosalicylates(5-asa) patients had participated to other clinical study in two months

Keywords: infliximab azathioprine